Spyre Therapeutics Inc（SYRE）財務資料SYRESpyre Therapeutics Inc

Evaluating the bottom line, Spyre Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.52%, provide a clear picture of how effectively SYRE converts its operational activities into shareholder value.

In the context of the broader market, SYRE competes directly with industry leaders such as TGTX and CYTK. With a market capitalization of $8.43B, it holds a significant position in the sector. When comparing efficiency, SYRE's gross margin of N/A stands against TGTX's 82.86% and CYTK's 80.46%. Such benchmarking helps identify whether Spyre Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Spyre Therapeutics has shown substantial growth with a current market capitalization of approximately $9.6 billion. Despite recent losses, the company has a strong current ratio of 18.53, indicating good liquidity. The gross margin is not explicitly provided, but the company is focused on high-potential monoclonal antibody therapies, which typically have favorable margins.